Literature DB >> 5812585

Phase II study of hexamethylmelamine (NSC 13875).

W L Wilson, J M Schroeder, H F Bisel, R Mrazek, R P Hummel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5812585     DOI： 10.1002/1097-0142(196901)23:1<132::aid-cncr2820230116>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

Review 1.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development.

Authors:  Deborah B Doroshow; James H Doroshow
Journal:  Cancer J       Date:  2019 Jul/Aug       Impact factor: 3.360

Review 3.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.

Authors:  M D'Incalci; E Erba; G Balconi; L Morasca; S Garattini
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.